Seattle Genetics, Inc. First Quarter Earnings Sneak Peek

Seattle Genetics, Inc. (NASDAQ:SGEN) will unveil its latest earnings on Tuesday, May 8, 2012. Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease.

Seattle Genetics, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for net loss of 12 cents per share, a narrower loss from the year-earlier quarter net loss of 30 cents. During the past three months, the average estimate has moved up from a loss of 25 cents. Between one and three months ago, the average estimate moved up. It has been unchanged at a loss of 12 cents during the last month.

Past Earnings Performance: The company is looking to beat analyst estimates for the third quarter in a row. Last quarter, it beat estimates with a loss of 24 cents per share against the mean estimate of 30 cents. In the prior quarter, the company reported net loss of 35 cents.

Investing Insights: What’s the Future of Microsoft’s Stock?

Wall St. Revenue Expectations: Analysts predict a rise of more than fourfold in revenue from the year-earlier quarter to $52.3 million.

Analyst Ratings: seven out of 12 analysts surveyed (58.3%) have a buy rating on Seattle Genetics. This falls under the mean analyst rating of 10 competitors, which average 71.6% buy ratings.

A Look Back: In the fourth quarter of the last fiscal year, the company’s loss narrowed to a loss of $27.2 million (23 cents a share) from a loss of $34.5 million (35 cents) a year earlier, beating analyst expectations. Revenue rose more than sixfold to $48.9 million from $8.1 million.

Key Stats:

On the top line, the company is looking to build on two-straight revenue increases with this earnings announcement. Revenue rose 29.2% in the third quarter of the last fiscal year before climbing again in the fourth quarter of the last fiscal year of the last fiscal year.

Stock Price Performance: Between March 6, 2012 and May 2, 2012, the stock price had risen $2.30 (13.2%), from $17.49 to $19.79. The stock price saw one of its best stretches over the last year between January 3, 2012 and January 12, 2012, when shares rose for eight straight days, increasing 12.4% (+$2.04) over that span. It saw one of its worst periods between April 2, 2012 and April 10, 2012 when shares fell for six straight days, dropping 11.7% (-$2.44) over that span.

(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)

Don’t Miss These Additional Hot Stories:

Why Are These Health Stocks Feeling Under the Weather?

What Do Americans Think About Gold?>>

Here’s How to Bet on a Baby Boom>>